Our Company

Prof. Nava Zisapel (Emeritus, Tel Aviv University), founder and CEO of Neurim Pharmaceuticals, is a renown neuroscientist with research focus on melatonin, sleep, and neurosecretion. Professor Zisapel is the principal author of over 200 papers in peer-reviewed journals and principal inventor of over 60 patents. She led the development and commercialization of the company’s first drugs and is deeply involved in discovering and developing new medicines that hold promise for patients with CNS-related conditions.

Since joining Neurim Pharmaceuticals in 2011, Adi Zisapel has served in several commercial roles, becoming the company’s Chief Commercial Officer in 2014. Her focus on developing the business brings impact both on Neurim's strategic partnerships worldwide and on the successful launch and performance of Neurim’s products, resulting in significant YoY growth. Adi has broadened Neurim’s global marketing, market access and sales activities, and is responsible for the development of strategic partner alliances while overseeing Neurim’s global subsidiaries. Adi holds a BSc in biotechnology engineering from the Technion (Israel Institute of Technology).

Guy Shachar joined Neurim in 2022 as VP Finance and Operations. Guy has more than 20 years of experience in senior financial management positions, and brings us deep understanding and experience in financial planning, accounting and the implementation of processes and high-end technologies to achieve measurable and sustainable results. Guy is a certified public accountant with a degree in Business Administration, a major in Accounting & Financing, and a LLM (Master of Law) degree.

Since 1997, Dr. Tali Nir has been Neurim's VP for Clinical and Regulatory Affairs, leading its global product registration and clinical development. During this time Tali has acted in various CNS fields including insomnia in adults and in the pediatric ASD population, Alzheimer’s disease, ocular hypertension, pain and sleep apnea. She has led phase 1-4 clinical studies of Neurim Pharmaceuticals’ products and pipeline, including Circadin and Slenyto, and their worldwide regulatory registration. Tali Nir is a Doctor of Veterinary Medicine with a degree from the Hebrew University of Jerusalem in Israel.

Dr. Moshe Laudon joined Neurim in 1992 bringing with him vast scientific and research experience. He was involved in the pharmaceutical development of Neurim's products and managed R&D functions, including drug discovery, pre-clinical, CMC and patent management. Dr. Laudon’s principal areas of research are the development of prolonged-release formulation concepts for oral drug delivery, and the investigation of novel indole derivatives. Moshe Laudon holds a Ph.D. in Neurobiochemistry from Tel-Aviv University and has published more than 80 papers and 10 patents.